MAY 30, 2016 9:53 AM PDT

Brain Cancer Survival Tied to 8 Immunity Genes

WRITTEN BY: Xuan Pham
A group of immune-related genes could predict survival for patients battling with a brain cancer type known as glioblastoma multiforme (GBM). The research identified 8 genes that seemed to modulate the prognosis of the disease. Researchers think knowing this genetic profile could guide doctors in making more informed treatment for their GMB patients.
 
Researchers identify immune genes tied to common, deadly brain cancer
Glioblastoma (GBM) is the most common and deadly form of primary brain cancer. In GBM, malignant glial cells form vast networks of tendrils throughout the brain, making it nearly impossible to surgically remove all the cancerous tissues. Dubbed as the “octopus tumor,” GBMs can evade even the most aggressive surgeries, chemotherapies, and radiotherapies, leaving patients with a five-year survival rate of less than 10%.
 

“We’ve had luck with other types of cancer in removing the brakes on the immune system to allow it to fight the tumors, but this has not been the case with glioblastoma,” said Anhua Wu, professor at the First Hospital of China Medical University in Shenyang, China, and senior study author. “If our discovery of these genes is validated in other studies, we could use this ‘gene signature’ to determine the best treatments or path of treatment.”
 
In the quest to identify the gene(s) involved with GBM survival, the team analyzed tumor samples fro 297patients with brain cancer. The patients were separated into those with low-grade glioma (170) and those with high-grade glioblastoma (127). Using genome sequencing, they found 322 genes that were related to the immune system. Of this, eight seemed to influence survival outcome. The eight genes were: FOXO3, IL6, IL10, ZBTB16, CCL18, AIMP1, FCGR2B, and MMP9.
 
From the list of eight genes, the team developed a signature profile that could classify patients as high- or low-risk. High-risk patients survived, on average, 348 days after diagnosis. This 145 days less than the low-risk patients, who survived an average of 493 days after diagnosis.
 
The same eight-gene signature was also validated in a larger sample of 536 glioblastoma samples. In addition, the prognostic value of these eight genes could also be extended to other forms of gliomas.
 
“The looming question in brain cancer research today is whether the launch of immunotherapy will help control an uncontrollable disease,” said Rifaat Bashir, a retired neurologist in Virginia and a Fellow of the American Academy of Neurology and the American Neurological Association. Bashir wrote an accompanying editorial, in which he stated: “While this study does not answer this question, it brings us one step closer to believing that one day we will be able to exploit the immune system to better treat glioblastoma.”

Additional source: American Academy of Neurology press release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 15, 2020
Immunology
Immune Memory to Thwart Recurring Cancer
JUL 15, 2020
Immune Memory to Thwart Recurring Cancer
Preventing cancer from returning in the body is an integral part of any anti-cancer treatment plan. New discoveries from ...
JUL 20, 2020
Cancer
Fighting Cancer with Black Pepper
JUL 20, 2020
Fighting Cancer with Black Pepper
In the never-ending search for the next treatment or cure, many researchers turn towards nature. The study of black pepp ...
JUL 23, 2020
Immunology
Cancer Therapy Reduces Lung Scarring
JUL 23, 2020
Cancer Therapy Reduces Lung Scarring
Scientists at the Stanford Institute for Stem Cell Biology and Regenerative Medicine have discovered a striking parallel ...
JUL 24, 2020
Cancer
A New Biomarker Candidate for Cancer Diagnostics
JUL 24, 2020
A New Biomarker Candidate for Cancer Diagnostics
One of the best tools in the fight against cancer is diagnostics. In 2018, colorectal cancer was the second most lethal ...
AUG 03, 2020
Cancer
Improving Diagnostics in Breast Cancer
AUG 03, 2020
Improving Diagnostics in Breast Cancer
Diagnostics is one of the essential tools in a physician’s toolkit. A good diagnostic test can identify whether a ...
AUG 27, 2020
Clinical & Molecular DX
Genetic Tool Predicts Breast Cancer Risk in Women of Asian Ancestry
AUG 27, 2020
Genetic Tool Predicts Breast Cancer Risk in Women of Asian Ancestry
  Many diseases such as breast cancer have both a strong genetic component, coupled with a variety of environmental ...
Loading Comments...